Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schrodinger, Inc.

http://www.schrodinger.com

Latest From Schrodinger, Inc.

IPO Update: 58 Drug Developers Raised $12.5bn Through Q3

The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with four additional initial public offerings on 1 October.

Financing Growth

Asia Deal Watch: Simcere, G1 Partner Globally On Myelopreservation Drug

Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.

Deals Business Strategies

Finance Watch: Biopharma Fundraising Impact Expected, But Not Apparent Yet

While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.

Financing Deals

IPO Update: Biopharma Stands Out Among Gloomy US Market

While COVID-19 closed the window for most initial public offerings late in the first quarter, drug developers continue to launch IPOs, generating an average return of nearly 21% year-to-date.

Financing Trends
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Digital Health
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
UsernamePublicRestriction

Register